{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"140","value":"258"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"}],"units":"Participants"}],"title":"Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"187","value":"568"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"}],"units":"Participants"}],"title":"4 hours Post-Dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.","id":"OG000","title":"Obinutuzumab + Venetoclax"}],"paramType":"MEAN","populationDescription":"Analysis population consisted of subjects from whom one or more serum samples were collected and who had received at least one dose of obinutuzumab and one dose of 400 mg venetoclax. Pre-dose and post-dose data may not come from the same participants. Total number analyzed is therefore higher than the number analyzed for each time point.","reportingStatus":"POSTED","timeFrame":"Pre-obinutuzumab infusion (0 hour) and end of obinutuzumab infusion on Day 1 Cycle 4","title":"Serum Concentrations of Obinutuzumab","type":"SECONDARY","unitOfMeasure":"μg/mL"}